10.1182/blood-2013-02-485888 - Three-year efficacy, safety, and surv...

This document has been corrected

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

10.1182/blood-2013-02-485888

Published Online: 2013-12-12

Journal: Blood•Publisher: American Society of Hematology

Authors: Alessandro M. Vannucchi•Andres Sirulnik•Claire N. Harrison•Deborah S. Hunter•Francesco Passamonti•Francisco Cervantes•Giovanni Barosi•Haifa Kathrin Al-Ali•Heinz Gisslinger•Jean-Jacques Kiladjian•Laurent Knoops•Mari McQuitty•Richard S. Levy•Tiziano Barbui•Viktoriya Stalbovskaya

This document has been corrected

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

10.1182/blood-2013-02-485888

Published Online: 2013-12-12

Journal: Blood

NOW

2016-12-22•Erratum

Cervantes F, Vannucchi AM, Kiladjian J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053.

10.1182/blood-2016-11-750505

* information provided by CrossRef

2016-12-22•Erratum

10.1182/blood-2016-11-750505

* information provided by CrossRef

2013-12-12•Published

2016-12-22•Erratum

10.1182/blood-2016-11-750505

* information provided by CrossRef

This document has been corrected

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

10.1182/blood-2013-02-485888

Published Online: 2013-12-12

Journal: Blood•Publisher: American Society of Hematology